Species‐specific restriction of complement by HRF20 (CD59) generated by cDNA transfection
- 1 July 1992
- journal article
- Published by Wiley in European Journal of Immunology
- Vol. 22 (7) , 1943-1946
- https://doi.org/10.1002/eji.1830220741
Abstract
The 20‐kDa homologous restriction factor (HRF20, CD59) is a phosphatidyl inositol‐anchored membrane glycoprotein that inhibits the formation of human complement membrane attack complexes. The cDNA of HRF20 was transfected into Chinese hamster ovary (CHO) cells resulting in expression of human HRF20 protein on the cell surface anchored via glycosylphosphatidyl inositol. The transfected CHO cells were resistant to human complement‐mediated cell killing. However, the cells remained sensitive to rat and guinea pig complement. Therefore, species specificity between HRF20 and complement is maintained in HRF20 generated on the CHO cells following transfection with HRF20 cDNA.Keywords
This publication has 20 references indexed in Scilit:
- Complete deficiency of 20 KDa homologous restriction factor (HRF20) and restoration with purified HRF20Biochemical and Biophysical Research Communications, 1989
- CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells.The Journal of Experimental Medicine, 1989
- 20 KDa homologous restriction factor of complement resembles T cell activating proteinBiochemical and Biophysical Research Communications, 1989
- Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria.Journal of Clinical Investigation, 1989
- A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complementInternational Immunology, 1989
- Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositolMolecular Immunology, 1989
- Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.The Journal of Experimental Medicine, 1985
- Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.The Journal of Experimental Medicine, 1984
- Restriction of alternative complement pathway activation by sialosylglycolipidsNature, 1982
- Effect of protease treatment on the sensitivity of tumor cells to antibody-GPC killingClinical Immunology and Immunopathology, 1978